Haugli projected, "We believe 2026 will be a breakout year for Enclave revenue growth, driven by stronger channel execution, direct enterprise sales and increased awareness of microsegmentation as a ...

Xeris Biopharma delivered record Q2 revenue, driven by Recorlev's rapid adoption, and is on track to achieve breakeven in Q3. Recorlev is the primary growth engine, while Gvoke provides steady ...

At year-end, tech-dominated markets such as Seattle and San Francisco saw annual growth in demand nearing 50 percent, with much more muted growth nationally, according to the Q4 VTS Office Demand ...